The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Visual illusions test how attentive one’s eyes are. In today’s visual illusion test, a dog is hiding among the polar bears in ...

How good are you at noticing details that others often overlook? Take this optical illusion test and see if you can ace it ...

Did you know your eyes can reveal diabetes, heart issues, or tumors? Discover which systemic diseases manifest through vision ...

In a subgroup analysis of patients with polypoidal choroidal vasculopathy, aflibercept 8 mg achieved similar vision gains to ...

Kalaris Therapeutics offers differentiated approach to neovascular AMD with its lead candidate TH103. Click here to read my ...

In visually impaired older adults, broken flooring, such as torn carpet, had the greatest fall risk at a 47% increase, followed by tripping hazards, like unsecured throw rugs or electrical cords, at ...

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injectionTH103 was ...

Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...